Trial Profile
Phase I bioavailability study of PA 10040, POZEN's proprietary combination of aspirin (100mg)/omeprazole (40mg), versus a European Union reference listed enteric-coated (EC) aspirin (100mg)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2013
Price :
$35
*
At a glance
- Drugs Aspirin/omeprazole (Primary) ; Aspirin
- Indications Cardiovascular disorders; Embolism and thrombosis; NSAID-induced ulcer
- Focus Pharmacokinetics
- 08 Aug 2013 New trial record
- 06 Aug 2013 Status changed from not yet recruiting to completed, based on results reported in a POZEN media release.